Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date
Costa Rica: These 8 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Costa Rica: These 8 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026" DrugPatentWatch.com thinkBiotech, 2025 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can OMONTYS (peginesatide acetate) generic drug versions launch?
Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 03, 2025
Generic Entry Controlled by: Costa Rica Patent 9,570
Patent Title: FORMULACIONES Y USOS DEL PEPTIDO RECEPTOR DE ERITROPOYETINA
OMONTYS is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries.
The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: Costa Rica Patent 11,259
Patent Title: BROMHIDRATO DE BUPROPION Y APLICACIONES TERAPUETICAS
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries.
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: Costa Rica Patent 9,609
Patent Title: FORMULACIONES DE UNA SAL DE BUPROPION DE LIBERACION MODIFICADA
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries.
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can BOSULIF (bosutinib monohydrate) generic drug versions launch?
Generic name: bosutinib monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 01, 2025
Generic Entry Controlled by: Costa Rica Patent 9,596
Patent Title: FORMAS CRISTALINAS DE 4-[(2,4-DICLORO-5-METOXIFENIL)AMINO]-6-METOXI-7-[3-(4-METIL-1-PIPERAZINIL)PROPOXI]-3-QUINOLINOCARBONITRILO Y METODOS PARA SU PREPARACION
BOSULIF is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF
See drug price trends for BOSULIF.
The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: Costa Rica Patent 9,783
Patent Title: INHIBIDORES MACROCICLICOS DEL VIRUS DE LA HEPATITIS C
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and forty patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can LYRICA CR (pregabalin) generic drug versions launch?
Generic name: pregabalin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2025
Generic Entry Controlled by: Costa Rica Patent 9,950
Patent Title: COMPOSICIONES FARMACEUTICAS SOLIDAS QUE CONTIENEN PREGABALINA
This drug has thirty-seven patent family members in thirty-three countries.
See drug price trends for LYRICA CR.
The generic ingredient in LYRICA CR is pregabalin. There are forty-one drug master file entries for this API. Fifty-five suppliers are listed for this generic product. Additional details are available on the pregabalin profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2026
Generic Entry Controlled by: Costa Rica Patent 10,329
Patent Title: DERIVADOS DE ESTIRILPIRIDINA Y SUS USOS PARA UNION A PLACAS AMILOIDES Y OBTENCION DE IMAGENES DE LAS MISMAS
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries.
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.
When can LASTACAFT (alcaftadine) generic drug versions launch?
Generic name: alcaftadine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 31, 2026
Generic Entry Controlled by: Costa Rica Patent 10,414
Patent Title: TRATAMIENTOS DE LAS ALERGIAS OCULARES
This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT
See drug price trends for LASTACAFT.
The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.
When can FARYDAK (panobinostat lactate) generic drug versions launch?
Generic name: panobinostat lactate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: Costa Rica Patent 10,440
Patent Title: POLIMORFOS DE N-HIDROXI-3-[4-[[[2-(2-METIL-1H-INDOL-3-YL)ETIL]AMINO]METIL]FENIL]2E-2-PROPENAMIDA
FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.
This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK
See drug price trends for FARYDAK.
The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.
Market Analysis and Financial Projection
More… ↓
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.